Pembrolizumab Approved for Classical Hodgkin Lymphoma

PembrolizumabThe FDA has now expanded the approved indications for pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme) to include both adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL, or cHL that has relapsed after two or more lines of therapy. The approval was based on efficacy data from the open-label phase 3 KEYNOTE-204 trial (NCT02684292), for which 304 adult patients with cHL previously treated with at least one multiagen...
Continue reading

Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma: John Kuruvilla, MD

This past weekend in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, John Kuruvilla, MD, presented results of the phase 3 KEYNOTE-204 trial, reporting that pembrolizumab significantly increased progression-free survival compared with brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma. In this interview with i3 Health, Dr. Kuruvilla, an Associate Professor of Medicine at the University of Toronto, discusses the challenges of treatin...
Continue reading

Copyright ┬ę 2020 Oncology Data Advisor. All rights reserved.